Impact assessment

Impact Assessment For The Continuation Of A Statutory Scheme To Control The Prices Of Branded Medicines In The NHS

A regulatory impact assessment for the continuation of a statutory scheme to control the prices of branded medicines in the NHS.

This was published under the 2005 to 2010 Labour government

Documents

Impact Assessment For The Continuation Of A Statutory Scheme To Control The Prices Of Branded Medicines In The NHS

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The NHS spends approximately £9 billion a year on branded prescription medicines. The Pharmaceutical Price Regulation Scheme (PPRS) controls their prices by regulating the profits that companies can make on these sales. It is not a conventional market with a single purchaser (the government) and manufacturers, which hold patents that provide temporary monopolies over supply of their products. A new PPRS was implemented from 1st January 2009, including, amongst other things, provision for a second cut in the price of branded medicines from 1st January 2010. In the absence of statutory fall-back measures, companies could avoid that price cut by choosing not to join the voluntary scheme.

Published 30 October 2009